

# 2014 Cancer ANNUAL REPORT



## I Chose West Florida Hospital

*"As a nurse, compassionate, supportive care has been my personal mission in providing care for patients and their families for many years. Recently, the tables were turned and I became the patient. The care I received from the physicians, staff and volunteers at West Florida Hospital went right along with my personal mission. I was treated with respect, prompt response to questions or concerns and excellent, compassionate care."*

Laura Maiberger

WEST FLORIDA HEALTHCARE

## West Florida Hospital Cancer Care Program

West Florida Hospital offers a comprehensive oncology/hematology program that includes caring, compassionate physicians, nurses, and a multitude of allied health professionals who are specially trained to care for patients with cancer and blood disorders.

**Our Cancer Program's high standards of care include:**

- Sophisticated diagnostics to detect cancer faster and help make treatments more effective.
- Specially trained oncology nurses, many of whom are oncology certified registered nurses that specialize in chemotherapy administration, treatment of side effects, blood product infusions and pain management.
- Patient/family education.
- Emotional support for patients and their families.
- Active Cancer Committee that brings together the expertise and perspectives of physicians from a variety of specialties and disciplines.
- Innovative treatment for liver cancer

On the West Florida Hospital campus is the West Florida Cancer Center where nationally recognized cancer care is delivered locally by physicians you know and trust.

At the West Florida Cancer Center, we offer technology to detect, pinpoint, and beat cancer. When battling cancer, you need every advantage on your side and we have access to the region's most advanced technology to help you beat cancer. The strength of our network of care lies in the expertise of our team and the arsenal of technology we have at our fingertips to develop an individualized treatment plan for each patient.

By choosing the West Florida Cancer Center, you will have access to:

- Comprehensive care including a range of state-of-the-art treatment options
- A Patient Navigator who will serve as your own personal guide to help you through all aspects of your cancer care. [Learn more about the Patient Navigator.](#)
- A multi-specialty team approach to coordinate the best treatment options
- Information about ongoing clinical trials and new treatment options
- Access to cancer-related information, education and support
- A cancer registry that collects data on type and stage of cancers and treatment results and offers life-long follow-up
- Quality care close to home

## Cancer Committee Membership 2014


Membership is comprised of physician representatives from Surgery, Medical Oncology, Radiation Oncology, Radiology, Pathology, and Psychosocial Services and non-physician representatives from Administration, Nursing, Education, Rehabilitation, Cancer Center, Patient Navigation, Quality Improvement, and Cancer Registry, as well as other respected members of the health care team.

ROLE	NAME
Cancer Committee Chair	Dr. Patrick Dial
Cancer Liaison Physician	Dr. North Davis
Cancer Conference Coordinator	Dr. Patrick Dial
Clinical Research Coordinator	Dr. Rami Owera
Psychosocial Services Coordinator	Dr. Joann Massey
Surgeon	Dr. Patrick Dial
Medical Oncologist	Dr. Rami Owera
Radiation Oncologist	Dr. Irfan Ahmed
Pathologist	Dr. North Davis/Dr. Andres Candela
Diagnostic Radiologist	Dr. Carl Blunck/Dr. Henry Lusane
Gastroenterologist	Dr. Lakshmi Gopal
Urologist	Dr. Anthony Doerr
Cancer Program Administrator	K. C. Donahey, COO/Dr. Terry Stallings
Community Outreach Coordinator	Nina Clark/Beth Matthews
Quality Improvement Coordinator	Debbie Wroten, VP/Brenda Pearson
Cancer Registry Quality Coordinator	Nicole Burmeister-Kintz, CTR
Oncology Nurse	Janet Haugen, RN/Kimberly Lawrence, RN
Cancer Center	Autumn Cook, Director
Patient Navigator	Rachel Forehand, RN
Case Management	Teresa Johnson, RN/Bryan Hudson, Director
Mammography	Angie Hyrczyk
Speech Rehabilitation	Linda Baily
Marketing	Kendrick Doidge
American Cancer Society	Jill Pait

## Cancer Program Practice Profile Reports (CP<sup>3</sup>R)

The West Florida Hospital Cancer Committee ensures that patients with cancer receive care according to nationally accepted measures. Compliance is measured through Commission on Cancer quality reporting tools such as the Cancer Program Practice Profile Reports (CP<sup>3</sup>R). The West Florida Hospital Cancer Committee reviews the quality of patient care utilizing such tools providing a platform for physicians to evaluate care within and across disciplines to discuss processes that work and to evaluate how processes can be improved to promote evidence-based practices. Below are the CP<sup>3</sup>R performance summaries that highlight cases treated at West Florida Hospital in 2013. We are proud that our cancer program exceeds all of the required performance standards as outlined by the Commission on Cancer.


When comparing CP<sup>3</sup>R measures with the State of Florida and all Commission on Cancer approved programs, West Florida Hospital stands out as a leader in delivering excellent quality care to patients.



HT – Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c or stage IB-III hormone receptor positive breast cancer (Accountability Measure)

CoC Standard = 90%


West Florida Hospital = 96.6%



MASTRT – Radiation therapy is considered or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with  $\geq 4$  positive regional lymph nodes (Accountability Measure)

CoC Standard = 90%


West Florida Hospital = 100%



BCSRT - Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer (Accountability Measure)

CoC Standard = 90%


West Florida Hospital = 95.2%



MAC - Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0, or stage IB-III hormone receptor negative breast cancer (Accountability Measure)

CoC Standard = 90%


West Florida Hospital = 100%



nBx - Image or palpation-guided needle biopsy (core of FNA) of the primary site is performed to establish diagnosis of breast cancer (Quality Improvement Measure)

CoC Standard = 80%


West Florida Hospital = 80.3%



ACT - Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC stage III (lymph node positive) colon cancer (Accountability Measure)

CoC Standard = 90%

West Florida Hospital = 100%



12RLN - At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer (Quality Improvement Measure)

CoC Standard = 85%

West Florida Hospital = 89.2%

## Cancer Conference

A multidisciplinary cancer conference is held weekly at West Florida Hospital with the first and third week of every month designated for breast cancer cases. Attending the conferences are surgeons, radiologists, pathologists, medical oncologists, radiation oncologists, and other specialty physicians as well as nurses, a patient care navigator, and other members of the hospital care team who are driven to provide the best quality of care to patients diagnosed with cancer. Treatment planning using evidence-based treatment guidelines as well as options for clinical trials are discussed in a multidisciplinary environment to provide the patient with the best care possible. In 2014, 144 cases were presented at Cancer Conference, and breast cancer was the leading primary site followed by colorectal, lung, and then pancreas as well as many more sites.


## Cancer Registry

A total of 826 new cancer cases were registered in 2014 at West Florida Hospital. Of those registered, 609 (74%) were analytic and 217 (26%) were non-analytic. Of all cancer patients seen in 2014, 52% were men and 48% were women. The top five primary sites, making up 65% of the total analytic cases for 2014 were:

Site	No. Cases	Stage						% of Analytic Cases
		0	I	II	III	IV	Unknown	
Lung	105	0	22	7	28	45	3	17
Breast	103	17	47	29	5	5	0	17
Prostate	77	0	12	50	10	4	1	13
Bladder	61	25	16	9	3	8	0	10
Kidney	47	0	32	4	2	9	0	8

### 2014 Treatment Modalities for Analytic Cases

\*Other to include multiple combination modalities with surgery, radiation, chemotherapy, hormones, and immunotherapy



## Monitoring Compliance with Evidence-Based Guidelines (Assessment of Evaluation and Treatment Planning Study)

Each year a physician member of the Cancer Committee performs a study to assess whether patients within the program are evaluated and treated according to evidence-based national treatment guidelines. Study results are presented to the Cancer Committee and documented in Cancer Committee minutes. Since non-small cell lung carcinoma accounts for about 85% of lung cancers and includes predominantly adenocarcinoma, identifying mutations in oncogenes can help determine which patients are more likely to benefit from a targeted therapy. Such oncogenes include EGFR (epidermal growth factor receptors) and ALK (anaplastic lymphoma receptor tyrosine kinase). The discovery of mutations in EGFR and the associated response to EGFR-targeting tyrosine kinase inhibitors have provided physicians with an effective tool in their approach to treatment of lung cancers. In 2013, the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) developed guidelines to recommend molecular testing with EGFR and ALK for a selection of patients with lung cancer. West Florida Hospital conducted a study in 2014 on whether EGFR molecular studies were being done on all adenocarcinomas of the lung. Pathology looked at all adenocarcinomas of the lung diagnosed at West Florida Hospital in 2012 and 2013 to identify if EGFR molecular studies were performed. There were a total of 56 adenocarcinomas of the lung reviewed. Out of these cases, 23 (41%) had EGFR molecular studies ordered. In October 2014, The American Society of Clinical Oncology (ASCO) endorsed the molecular testing guidelines recommended by CAP/IASLC/AMP to offer EGFR and ALK testing to all patients with lung adenocarcinoma. In combination with the results of our study and the recommended guidelines, EGFR molecular studies are now being ordered on all adenocarcinomas of the lung at West Florida Hospital. These molecular tests will help guide physicians in determining the optimal therapy for patients diagnosed with lung cancer.



## Community Outreach

Community engagement is a vital part of West Florida Hospital's commitment to patient care and education. In 2014, several support meetings were held throughout the year for oral, head, and neck cancer support. Dr. Kevin Welch of Dermatology held a seminar, "Red Spots, Brown Spots, Skin Cancer – How to Tell the Difference." This seminar attracted 66 people with 53 having skin screenings and a finding of 21 abnormal skin screens. Attendees with abnormal skin screens were given referrals to dermatologists who would be able to discuss their results and provide further treatment if necessary. Dr. Brett Parra of Urology attracted 17 people to a seminar, "Men's Night Out: Straight Talk About Prostate Screenings." Fifteen men had digital exams, and two abnormal PSAs were found. Both were referred to a urologist for further follow-up. With positive feedback from these seminars and support groups, West Florida Hospital will continue its commitment in providing quality patient care and education throughout the community.

### GLOSSARY

**Cancer Program Practice Profile Reports (CP<sup>3</sup>R).** Reporting tool to provide comparative information to assess adherence to and consideration of standard of care therapies for major cancers

**Adenocarcinoma.** A malignant tumor formed from glandular structures in epithelial tissue

**Oncogene.** A gene that in certain circumstances can transform a cell into a tumor cell

**Epidermal Growth Factor Receptors (EGFR).** Protein found on surface of some cells and to which epidermal growth factor binds, causing the cells to divide; found at abnormally high levels on the surface of many types of cancer cells, so these cells may divide excessively in the presence of epidermal growth factor.

**Anaplastic Lymphoma Kinase (ALK).** A gene that makes the protein anaplastic lymphoma kinase which may be involved in cell growth; mutated forms of the ALK gene and protein have been found in some types of cancer, including neuroblastoma, non-small cell lung cancer, and anaplastic large cell lymphoma. These changes may increase the growth of cancer cells; checking for changes in ALK gene in tumor tissue may help to place cancer treatment.

**College of American Pathologist (CAP).** National professional organization of board-certified pathologists.

**International Association for the Study of Lung Cancer (IASLC).** Global organization dedicated to the study of lung cancer

**Association for Molecular Pathology (AMP).** Organization that focuses on the study and diagnosis of disease through the examination of molecules within organs, tissues, or bodily fluids.

**American Society of Clinical Oncology (ASCO).** Professional organization representing physicians of all oncology subspecialties who care for people with cancer.